The Council of European Union Health Ministers has adopted "far-reaching conclusions on public health strategies to combat neurodegenerative diseases associated with aging, in particular Alzheimer's disease," according to Alzheimer Europe, a representative body for AD patient groups across the region. Coming at the end of the French presidency, the policy announcement "clearly recognizes Alzheimer's disease as a priority for European action and calls on member states to develop national strategies or action plans in this field aimed at improving the quality of life of patients and their carers," the group adds.
Among the measures agreed by the Council of Ministers, the European Commission has been asked to adopt an initiative in 2009 which would strengthen European research collaboration, as well as exchange best practices on: prevention; early diagnosis; health and social care treatments; and rehabilitation. The Commission is also expected to consider the ethical dimension of AD and the protection of patients' rights. The conclusions also make a clear reference to the campaign of Alzheimer Europe and its member organizations to make AD a public health priority.
Jean Georges, executive director of Alzheimer Europe, welcomed the EU initiative. He said: "Alzheimer Europe would like to congratulate the French presidency on the significant achievement of reaching a consensus amongst all member states and the European Commission to make Alzheimer's disease and other forms of dementia a European priority." He added that 6.1 million Europeans are currently living with a form of dementia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
| Headless Content Management with Blaze